| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/02/2002 | US6413719 KCNQ2 and KCNQ3-potassium channel genes which are mutated in benign familial neonatal convulsions (BFNC) and other epilepsies |
| 07/02/2002 | US6413533 Administering antiestrogen |
| 07/02/2002 | US6413514 Methods of using antibodies against human CD40 |
| 07/02/2002 | US6413507 Modified polyether |
| 07/02/2002 | CA2333528C A stabilized antihistamine syrup containing aminopolycarboxylic acid as stabilizer |
| 07/02/2002 | CA2253080C 5-substituted picolinic acid compounds and their production process |
| 07/02/2002 | CA2201163C Utilization of an extract of at least one iridacea in the treatment of wrinkles |
| 07/02/2002 | CA2194984C 4-indole derivatives as serotonin agonists and antagonists |
| 07/02/2002 | CA2184908C Human osteoclast-derived cathepsin |
| 07/02/2002 | CA2124315C Nitroaniline derivatives and their use as antitumor agents |
| 07/02/2002 | CA2082960C An apparatus for preparing a concentrate of coagulation factors, such as fibrinogen, from a blood sample |
| 07/02/2002 | CA2047283C Pyrazolopyridine compound and processes for preparation thereof |
| 07/02/2002 | CA2040204C Chelating compounds and their use |
| 07/02/2002 | CA2018149C Aminoketone compounds |
| 06/27/2002 | WO2002050536A2 Replication assay for detecting anti-viral substances |
| 06/27/2002 | WO2002050289A1 Methods for the production of multimeric proteins, and related compositions |
| 06/27/2002 | WO2002050287A2 Multifunctional protease inhibitors and their use in treatment of disease |
| 06/27/2002 | WO2002050286A2 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
| 06/27/2002 | WO2002050284A2 Oxidoreductases |
| 06/27/2002 | WO2002050283A2 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 06/27/2002 | WO2002050279A2 Nucleic acid-associated proteins |
| 06/27/2002 | WO2002050278A2 Novel human secreted proteins and polynucleotides encoding the same |
| 06/27/2002 | WO2002050255A2 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof |
| 06/27/2002 | WO2002050122A2 Means for the diagnosis and therapy of ctcl |
| 06/27/2002 | WO2002050119A2 Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes |
| 06/27/2002 | WO2002050115A1 Modified tachykinin receptors |
| 06/27/2002 | WO2002050112A2 Isolation of purified tgf- 1 and tgf- 2 from bone tissue |
| 06/27/2002 | WO2002050102A2 Inhibitors of the e2f-1/cyclin interaction for cancer therapy |
| 06/27/2002 | WO2002050097A2 Anti-allergic complex molecules |
| 06/27/2002 | WO2002050096A1 Sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| 06/27/2002 | WO2002050079A1 Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors |
| 06/27/2002 | WO2002050078A1 Novel substituted imidazotriazinones as pde ii-inhibitors |
| 06/27/2002 | WO2002050073A1 Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors |
| 06/27/2002 | WO2002050071A1 Thiazolyl inhibitors of tec family tyrosine kinases |
| 06/27/2002 | WO2002050070A2 Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists |
| 06/27/2002 | WO2002050068A1 Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
| 06/27/2002 | WO2002050066A2 Pyrazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002050065A2 Pyrazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002050064A1 Substituted pyrrolidines as ccr-3 receptor antagonists |
| 06/27/2002 | WO2002050051A1 Chemical compounds |
| 06/27/2002 | WO2002050049A1 1,1-dioxo-2h-1, 2-benzothiazine-3-carboxamide derivatives, method for preparing same and pharmaceutical compositions comprising same |
| 06/27/2002 | WO2002050047A1 Substitued oxazoles and thiazoles as hppar alpha agonists |
| 06/27/2002 | WO2002050046A1 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen c-proteinase inhibitors |
| 06/27/2002 | WO2002050043A1 Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof |
| 06/27/2002 | WO2002050041A1 Dihydroindole and tetrahydroquinoline derivatives |
| 06/27/2002 | WO2002050039A1 Urea and urethane derivatives as integrin inhibitors |
| 06/27/2002 | WO2002050034A2 Tetracyclic carbazole derivates and their use as spla2 inhibitors |
| 06/27/2002 | WO2002050033A1 Benzo(f) isoindol derivatives and their use as ep4 receptor ligands |
| 06/27/2002 | WO2002050032A1 Naphthalene derivatives which bind to the ep4 receptor |
| 06/27/2002 | WO2002050031A1 Indole derivatives |
| 06/27/2002 | WO2002050030A2 Cycloalkylfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases |
| 06/27/2002 | WO2002050029A2 Tetracyclic derivatives as spla2 inhibitors |
| 06/27/2002 | WO2002050028A2 Substituted benzoindoles as spla2 inhibitors |
| 06/27/2002 | WO2002050027A1 Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
| 06/27/2002 | WO2002050021A1 Nitric oxide synthase inhibitor phosphate salt |
| 06/27/2002 | WO2002050019A2 Diamines as modulators of chemokine receptor activity |
| 06/27/2002 | WO2002049714A2 Electrically responsive promoter system |
| 06/27/2002 | WO2002049669A2 Electrically responsive promoter system |
| 06/27/2002 | WO2002049666A2 Mycoplasma hyopneumoniae bacterin vaccine |
| 06/27/2002 | WO2002049656A1 External skin preparations and process for producing the same |
| 06/27/2002 | WO2002049652A1 Method of treatment |
| 06/27/2002 | WO2002049650A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives |
| 06/27/2002 | WO2002049649A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) |
| 06/27/2002 | WO2002049646A1 Therapeutic combination of amlodipine and benazepril/benazeprilat |
| 06/27/2002 | WO2002049645A1 Therapeutic combination of amlodipine and benazepril |
| 06/27/2002 | WO2002049640A1 Triglyceride depressant composition |
| 06/27/2002 | WO2002049634A2 Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect |
| 06/27/2002 | WO2002049626A2 The use of ppar-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired pasticity |
| 06/27/2002 | WO2002049624A2 Novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists |
| 06/27/2002 | WO2002049622A2 Transdermal system containing a novel high potency progestagen |
| 06/27/2002 | WO2002049599A2 Filtering composition containing a 1,3,5-triazine derivative, a dibenzoylmethane derivative, and a 4,4-diarylbutadiene compound |
| 06/27/2002 | WO2002049593A2 Use of dna repair enzymes as mmp-1 inhibitors |
| 06/27/2002 | WO2002049577A2 Analogues of thiocoraline and be-22179 |
| 06/27/2002 | WO2002049575A2 Method and composition for the treatment of diabetic neuropathy |
| 06/27/2002 | WO2002049413A2 Thrombopoietin mimetics |
| 06/27/2002 | WO2002034232A3 Use of carotenoids for treating ageing symptoms |
| 06/27/2002 | WO2002034231A3 Use of the association of at least an plant extract of genus rosmarinus and of at least a carotenoid |
| 06/27/2002 | WO2002030879A3 Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors |
| 06/27/2002 | WO2002030390A3 Method for producing powdery formulations |
| 06/27/2002 | WO2002030353A3 NF-λB INHIBITORS |
| 06/27/2002 | WO2002026935A3 TGF-β INHIBITORS AND METHODS |
| 06/27/2002 | WO2002022602A3 Triazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002022592A3 Substituted urea neuropeptide y y5 receptor antagonists |
| 06/27/2002 | WO2002020822A3 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 06/27/2002 | WO2002020566A3 NOVEL MMP-2 DERIVATIVES FOR USE AS INHIBITORS OF INTEGRIN αVβ¿3? |
| 06/27/2002 | WO2002016548A3 Novel g protein-coupled receptor |
| 06/27/2002 | WO2002016433A3 Two receptors of meiosis activating sterols designated sam1a and sam1b |
| 06/27/2002 | WO2002009704A3 Pharmaceutical composition for transdermal delivery of befloxatone |
| 06/27/2002 | WO2002008231A3 Biologically active macrolides, compositions, and uses thereof |
| 06/27/2002 | WO2002007516A3 Uses for nad synthetase inhibitors |
| 06/27/2002 | WO2001096298A3 1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase |
| 06/27/2002 | WO2001096286A3 Urokinase inhibitors |
| 06/27/2002 | WO2001094381A3 Novel compounds of the n-acylamino-amide family, compositions comprising same, and uses |
| 06/27/2002 | WO2001092267A3 Dihydropyridine compounds for the inhibition of calcium-influx |
| 06/27/2002 | WO2001082858A3 Novel compounds for the treatment of inflammatory and cardiovascular diseases |
| 06/27/2002 | WO2001080857A9 Zolpidem hemitartrate |
| 06/27/2002 | WO2001076584A3 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases |
| 06/27/2002 | WO2001073025A3 Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains |
| 06/27/2002 | WO2001054680A3 Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor |
| 06/27/2002 | WO2001049662A3 Carbazole derivatives as inhibitors of spla2 |